Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18890841 | 0.89 | USP30 (0.39) | SMARCA2SMARCA4PBRM1SETD7GPR119 | |
| SCHEMBL18863973 | 0.86 | PSMB5 (0.41) | PSMB5 | |
| SCHEMBL18863974 | 0.86 | PSMB5 (0.41) | PSMB5 | |
| SCHEMBL18864031 | 0.86 | PSMB5 (0.41) | PSMB5 | |
| SCHEMBL14735205 | 0.84 | VEGFA (0.43) | SMARCA2SMARCA4PBRM1PSMB5 | |
| SCHEMBL14735201 | 0.81 | PARP1 (0.43) | PSMB5 | |
| SCHEMBL18863989 | 0.79 | GPR119 (0.44) | GPR119PSMB5 | |
| SCHEMBL18864002 | 0.76 | PDE4B (0.39) | GPR119 | |
| SCHEMBL18864000 | 0.76 | PDE4B (0.39) | GPR119 | |
| SCHEMBL18864020 | 0.76 | MAPT (0.35) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | PIM3, PIM1, PIM2 | SMARCA2 2425/4885SMARCA4 1803/4885PBRM1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.